Drug Trial Radar · NCT02135315
Intensive Arterial Pressure Control in Acute Coronary Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,500
Actual
Start
Mar 2014
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- University of MonastirAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Emergency NGO Onlus
- First posted
- May 9, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The intensive arterial pressure control in acute coronary syndrome (ACS) during the first 24 hours can improve the prognosis in the short and long term. the study compare two treatment strategies (standard and intensive treatment) to assess their efficacy and safety in the treatment of acute coronary syndrome.
Conditions
- Acute Coronary Syndrome
Interventions
Isosorbide DinitrateDrug
administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
Primary outcomes
What the sponsor says the trial is designed to measure.
- mortalityTime frame: 12 months
- major cardiovascular events (MACE)Time frame: 12months
- combined mortality and MACE rateTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
university of Monastir
Monastir, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.